Evidence map›Paper›PMID 39943810›Full record

ReviewFuture cardiology2025

The role of single-pill ACE inhibitor/ccb combination for hypertension: an Algerian view via the nominal group technique.

Brahim Kichou, Abed Bouraghda, Hadj Mohamed Ali Lahmar, Sofiane Amara, Yazid Aoudia, Yasmina Benchabi, Farid Haddoum, Adjia Kachenoura, Nadia Laredj, Leila Manamani and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Brahim KichouCardiology Department, University Hospital of Tizi Ouzou, Tizi Ouzou, Algeria.
Abed BouraghdaCardiology Department, University Hospital of Frantz Fanon, Blida, Algeria.ORCID 0000-0002-7720-1850
Hadj Mohamed Ali LahmarCardiovascular Exploration Centre "EST ORANAIS", Oran, Algeria.
Sofiane AmaraPrivate Cardiology Clinic, Cité Daksi Abdessalem, Constantine, Algeria.
Yazid AoudiaCardiology Department, Tipasa Hospital, Blida, Algeria.
Yasmina BenchabiCardiology Department, University Hospital of Constantine, Constantine, Algeria.
Farid HaddoumNephrology Department, University Hospital of Mustapha Bacha, Algiers, Algeria.
Adjia KachenouraCardiology Department, University Hospital of Bejaia, Blida, Algeria.
Nadia LaredjCardiology Department, University Hospital of Oran, Oran, Algeria.ORCID 0000-0001-5248-1035
Leila ManamaniCardiology Department, University Hospital of Annaba, Blida, Algeria.
Mohamed Tahar Chafik BouafiaCardiology Department, University Hospital of Frantz Fanon, Blida, Algeria.
Mohamed ChettibiCardiology Department, University Hospital of Beni Messous, Algiers, Algeria.ORCID 0000-0002-5969-5797

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Around one-third of adults in Algeria have hypertension, but > 40% are unaware they have the disease, and of those receiving treatment, only ~ 20-30% have adequate blood pressure (BP) control. Recommended starting treatment is an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker plus a calcium channel blocker (CCB) or diuretic. A single-pill combination of perindopril/amlodipine (ACEi/CCB) recently became available in Algeria. Twelve Algerian hypertension experts reviewed the clinical evidence regarding this therapeutic combination to determine its potential role for hypertension management in Algeria. The evidence indicated that this combination reduces cardiovascular outcomes and visit-to-visit BP variability, effectively controls 24-hour BP, and is well tolerated. In conclusion, the perindopril/amlodipine SPC provides a valuable new treatment option for hypertension in Algeria.

Indexed as

AmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureCalcium Channel BlockersHypertensionPerindoprilAlgeriaDrug CombinationsHumansAmlodipineamlodipine, perindopril drug combinationAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCalcium Channel BlockersDrug CombinationsPerindoprilAlgeriaamlodipinecardiovascular diseasehypertensionmortalityNorth Africaperindopril

Identifiers

PMID39943810
PMCPMC11875506

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.